University of Paris-Sud is a French university distributed among several campuses in the southern suburb of Paris . The main campus is located in Orsay . This university is a member of the UniverSud Paris.Paris-Sud is one of the largest and most renowned French universities, particularly in science and mathematics. Paris-Sud is ranked 2nd in France, 7th in Europe and 39th worldwide by the 2013 Academic Ranking of World Universities . Furthermore, in this latest edition of ARWU ranking, the university is ranked 15th globally in the field of Natural science and Mathematics; in the five general subject rankings, the university is ranked 7th in mathematics and 19th in physics. Wikipedia.
French Institute of Health, Medical Research, French National Center for Scientific Research, University of Paris Descartes, Fondation Imagine, University Paris Diderot, University Paris - Sud and Assistance Publique Hopitaux De Paris Aphp | Date: 2015-06-19
The present invention concerns a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for simultaneous or sequential use in the treatment of a drug resistant cancer and/or in prevention of tumor relapse in a patient suffering from cancer. The present invention also relates to a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for increasing, restoring or enhancing sensitivity of a patient suffering from cancer to a chemotherapeutic drug in a patient suffering from cancer.
Cisbio Bioassays, French National Center for Scientific Research and University Paris - Sud | Date: 2017-05-10
The present invention relates to anti- metabotropic glutamate receptor subtype 2 (mGluR2) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.
French Institute of Health, Medical Research, University Paris - Sud and University of Bordeaux 1 | Date: 2016-12-28
The present invention relates to polypeptides and their uses as apelin inhibitors. More particularly, the present invention relates to a polypeptide comprising the sequence as set forth in SEQ ID NO:1 wherein at least one arginine residue at position 18, 19, 22 or 23 has been substituted or deleted.
University Paris - Sud | Date: 2017-01-25
The invention relates to a method for inducing human cholangiocyte differentiation of progenitor cells called hepatoblasts. More specifically, the invention relates to a method for differentiating hepatoblasts to cholangiocytes by culturing said hepatoblasts with a particular medium having interleukin-6 (IL-6) activity. The differentiation method can specifically induce cholangiocyte differentiation from hepatoblasts, and the human cholangiocytes differentiated according to the invention may be useful for drug discovery for treatment of cholangiopathies and bioengineered livers.
French National Center for Scientific Research and University Paris - Sud | Date: 2017-02-15
The invention relates to compounds which are inhibitors of the polymerisation of tubulin, to the methods for the production thereof, and to the uses of same.
French National Center for Scientific Research, Institute Gustave Roussy, Cellvax and University Paris - Sud | Date: 2017-04-12
The invention relates to an antibody which is directed against galectin9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer.
Imperial Innovations Ltd, Institute Pasteur Paris and University Paris - Sud | Date: 2017-05-31
A Dengue virus Envelope Dimer Epitope (EDE) wherein the EDE: c) spans the polypeptides of a Dengue virus Envelope polypeptide dimer; and/or d) is presented on a dimer of Envelope proteins; and/or c) is formed from consecutive or non-consecutive residues of the envelope polypeptide dimer, wherein the dimer is a homodimer or heterodimer of native and/or mutant envelope polypeptides, from any one or two of DENV-1, DENV-2, DENV-3 and DENV-4. The EDE may be a stabilized recombinant dengue virus envelope glycoprotein E ectodomain (sE) dimer, wherein the dimer is: covalently stabilized with at least one disulphide inter-chain bond between the two sE monomers, and/or covalently stabilized with at least one sulfhydryl-reactive crosslinker between the two sE monomers, and/or covalently stabilized by linking the two sE monomers through modified sugars; and/or, covalently stabilised by being formed as a single polypeptide chain, optionally with a linker region, optionally a Glycine Serine rich linker region, separating the sE sequences, and/or non-covalently stabilized by substituting at least one amino acid residue in the amino acid sequence of at least one sE monomer with at least one bulky side chain amino acid, at the dimer interface or in domain 1 (D1) / domain 3 (D3) linker of each monomer. A compound, for example an antibody or antibody fragment that can neutralise more than one Dengue virus serotype, for example an antibody that can bind to an EDE of the invention.
University Paris - Sud and French National Center for Scientific Research | Date: 2017-02-08
The invention relates to complexes comprising a solid support and a material with a matrix structure comprising domains complexing rare earths or strategic metals. The invention also relates to the method for the production of said complexes and to the use thereof for extracting or separating the rare earths or the strategic metals in an aqueous or organic medium.
University Paris - Sud and French National Center for Scientific Research | Date: 2017-05-24
The invention relates to an electronic device with electrical supply circuit (12m), with variable capacitor (11, 211, Cv) varying through alternating mechanical movement (10). The supply comprises, in the form of passive components and with no means of synchronization: - generating branch (21) comprising in series the variable capacitor and a bias capacitor (212, C1), which is wired in parallel with a rectifying circuit (23, 23) and a storage branch (24), between: base node (NB), on the variable capacitor side, an output node (S), on the bias capacitor side (211, C1); - unidirectional charge return branch (22): to the generating branch, through a bias node (P) between variable capacitor and bias capacitor, from the rectifier, receiving part of the electrical energy produced; the circuit comprises a voltage multiplier (MT) connected to the bias node (P) so as to apply a voltage multiplied with respect to that existing in between the output node, and - the base node (NB) or one (OUT) of the ends of the storage branch.
Goerbig M.O.,University Paris - Sud
Reviews of Modern Physics | Year: 2011
The basic aspects of electrons in graphene (two-dimensional graphite) exposed to a strong perpendicular magnetic field are reviewed. One of its most salient features is the relativistic quantum Hall effect, the observation of which has been the experimental breakthrough in identifying pseudorelativistic massless charge carriers as the low-energy excitations in graphene. The effect may be understood in terms of Landau quantization for massless Dirac fermions, which is also the theoretical basis for the understanding of more involved phenomena due to electronic interactions. The role of electron-electron interactions both in the weak-coupling limit, where the electron-hole excitations are determined by collective modes, and in the strong-coupling regime of partially filled relativistic Landau levels are presented. In the latter limit, exotic ferromagnetic phases and incompressible quantum liquids are expected to be at the origin of recently observed (fractional) quantum Hall states. Furthermore, the electron-phonon coupling in a strong magnetic field is discussed. Although the present review has a dominant theoretical character, a close connection with available experimental observation is intended. © 2011 American Physical Society.